Cellebrite DI (CLBT) Stock Forecast, Price Target & Predictions
CLBT Stock Forecast
Cellebrite DI stock forecast is as follows: an average price target of $20.00 (represents a -11.19% downside from CLBT’s last price of $22.52) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
CLBT Price Target
The average price target for Cellebrite DI (CLBT) is $20.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $17.00. This represents a potential -11.19% downside from CLBT's last price of $22.52.
CLBT Analyst Ratings
According to 7 Wall Street analysts, Cellebrite DI's rating consensus is 'Buy'. The analyst rating breakdown for CLBT stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cellebrite DI Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Tomer Zilberman | Bank of America Securities | $20.00 | $18.11 | 10.47% | -11.19% |
| Sep 25, 2024 | Jeff Van Rhee | Craig-Hallum | $23.00 | $16.86 | 36.38% | 2.13% |
| Aug 16, 2024 | Eric Martinuzzi | Loop Capital Markets | $17.00 | $16.14 | 5.30% | -24.51% |
| Aug 16, 2024 | Tomer Zilberman | Bank of America Securities | $17.00 | $14.96 | 13.64% | -24.51% |
| Apr 01, 2024 | Jeff Van Rhee | Craig-Hallum | $16.00 | $11.08 | 44.40% | -28.95% |
The latest Cellebrite DI stock forecast, released on Oct 23, 2024 by Tomer Zilberman from Bank of America Securities, set a price target of $20.00, which represents a 10.47% increase from the stock price at the time of the forecast ($18.11), and a -11.19% decrease from CLBT last price ($22.52).
Cellebrite DI Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $21.50 | $18.60 |
| Last Closing Price | $22.52 | $22.52 | $22.52 |
| Upside/Downside | -100.00% | -4.53% | -17.41% |
In the current month, the average price target of Cellebrite DI stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cellebrite DI's last price of $22.52. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 25, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 16, 2024 | Lake Street | Buy | Buy | Hold |
| Aug 16, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Aug 16, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 24, 2024 | Lake Street | Buy | Buy | Hold |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 19, 2024 | Lake Street | Buy | Initialise | |
| Apr 01, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Apr 01, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Mar 13, 2024 | William Blair | Outperform | Upgrade | |
| Feb 16, 2024 | Bank of America Securities | Buy | Upgrade | |
| Mar 14, 2023 | Needham | Buy | Buy | Hold |
Cellebrite DI's last stock rating was published by Craig-Hallum on Sep 25, 2024. The company gave CLBT a "Buy" rating, the same as its previous rate.
Cellebrite DI Financial Forecast
Cellebrite DI Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $71.23M | $74.02M | $71.67M | $62.57M | $62.38M | $67.91M | $65.89M |
| Avg Forecast | $147.43M | $142.88M | $131.17M | $125.44M | $126.71M | $121.90M | $111.94M | $106.18M | $107.27M | $102.06M | $91.94M | $85.34M | $85.56M | $82.13M | $72.52M | $69.44M | $74.53M | $72.13M | $69.14M | $62.58M | $63.99M | $59.25M |
| High Forecast | $149.71M | $145.09M | $133.20M | $127.38M | $128.67M | $123.78M | $113.67M | $107.90M | $108.44M | $103.64M | $91.94M | $85.34M | $88.14M | $84.33M | $73.64M | $70.52M | $75.68M | $72.13M | $69.14M | $62.58M | $63.99M | $59.25M |
| Low Forecast | $145.10M | $140.62M | $129.09M | $123.46M | $124.71M | $119.97M | $110.16M | $104.46M | $106.42M | $100.45M | $91.94M | $85.34M | $82.44M | $80.50M | $71.38M | $68.34M | $73.35M | $72.13M | $69.14M | $62.58M | $63.99M | $59.25M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.99% | 0.99% | 0.91% | 1.00% | 1.06% | 1.11% |
Cellebrite DI's average Quarter revenue forecast for Jun 23 based on 3 analysts is $72.52M, with a low forecast of $71.38M, and a high forecast of $73.64M. CLBT's average Quarter revenue forecast represents a 1.81% increase compared to the company's last Quarter revenue of $71.23M (Mar 23).
Cellebrite DI EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.58M | $12.19M | $1.22M | $-3.34M | $166.00K | $105.85M | $34.63M |
| Avg Forecast | $9.03M | $8.76M | $8.04M | $7.69M | $7.77M | $7.47M | $6.86M | $6.51M | $6.57M | $6.25M | $5.63M | $5.23M | $5.24M | $5.03M | $4.44M | $4.26M | $4.57M | $5.07M | $4.86M | $4.40M | $4.50M | $4.17M |
| High Forecast | $9.17M | $8.89M | $8.16M | $7.81M | $7.89M | $7.59M | $6.97M | $6.61M | $6.65M | $6.35M | $5.63M | $5.23M | $5.40M | $5.17M | $4.51M | $4.32M | $4.64M | $5.07M | $4.86M | $4.40M | $4.50M | $4.17M |
| Low Forecast | $8.89M | $8.62M | $7.91M | $7.57M | $7.64M | $7.35M | $6.75M | $6.40M | $6.52M | $6.16M | $5.63M | $5.23M | $5.05M | $4.93M | $4.37M | $4.19M | $4.50M | $5.07M | $4.86M | $4.40M | $4.50M | $4.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.61% | 2.67% | 0.24% | -0.69% | 0.04% | 23.52% | 8.31% |
3 analysts predict CLBT's average Quarter EBITDA for Jun 23 to be $4.44M, with a high of $4.51M and a low of $4.37M. This is 72.07% upper than Cellebrite DI's previous annual EBITDA (Mar 23) of $2.58M.
Cellebrite DI Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-40.60M | $7.08M | $25.09M | $33.20M | $55.44M | $51.87M | $8.14M |
| Avg Forecast | $5.39M | $8.12M | $1.80M | $-2.25M | $17.01M | $18.03M | $11.90M | $8.68M | $12.90M | $15.59M | $7.57M | $5.05M | $6.68M | $5.33M | $3.18M | $1.65M | $10.96M | $994.75K | $2.70M | $2.49M | $3.48M | $1.33M |
| High Forecast | $5.50M | $8.29M | $1.84M | $-2.21M | $17.35M | $18.39M | $12.14M | $8.86M | $14.19M | $15.90M | $7.71M | $5.07M | $6.81M | $5.44M | $3.24M | $1.69M | $11.18M | $994.75K | $2.70M | $2.49M | $3.48M | $1.33M |
| Low Forecast | $5.28M | $7.96M | $1.76M | $-2.30M | $16.66M | $17.66M | $11.65M | $8.50M | $10.32M | $15.26M | $7.44M | $5.03M | $5.57M | $4.27M | $3.11M | $1.62M | $10.73M | $994.75K | $2.70M | $2.49M | $3.48M | $1.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.57% | 0.65% | 25.22% | 12.30% | 22.29% | 14.90% | 6.14% |
Cellebrite DI's average Quarter net income forecast for Mar 23 is $1.65M, with a range of $1.62M to $1.69M. CLBT's average Quarter net income forecast represents a -76.65% decrease compared to the company's last Quarter net income of $7.08M (Dec 22).
Cellebrite DI SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $37.56M | $32.48M | $36.59M | $35.40M | $33.77M | $29.80M | $40.60M |
| Avg Forecast | $73.21M | $70.95M | $65.14M | $62.29M | $62.92M | $60.53M | $55.58M | $52.73M | $53.27M | $50.68M | $45.66M | $42.38M | $42.49M | $40.78M | $36.01M | $34.48M | $37.01M | $35.82M | $34.33M | $31.07M | $31.77M | $29.42M |
| High Forecast | $74.34M | $72.05M | $66.14M | $63.25M | $63.90M | $61.47M | $56.44M | $53.58M | $53.85M | $51.47M | $45.66M | $42.38M | $43.77M | $41.87M | $36.57M | $35.02M | $37.58M | $35.82M | $34.33M | $31.07M | $31.77M | $29.42M |
| Low Forecast | $72.05M | $69.83M | $64.10M | $61.31M | $61.93M | $59.58M | $54.71M | $51.87M | $52.85M | $49.88M | $45.66M | $42.38M | $40.94M | $39.97M | $35.44M | $33.94M | $36.42M | $35.82M | $34.33M | $31.07M | $31.77M | $29.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.88% | 1.02% | 1.03% | 1.09% | 0.94% | 1.38% |
Cellebrite DI's average Quarter SG&A projection for Jun 23 is $36.01M, based on 3 Wall Street analysts, with a range of $35.44M to $36.57M. The forecast indicates a -4.12% fall compared to CLBT last annual SG&A of $37.56M (Mar 23).
Cellebrite DI EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.22 | $0.04 | $0.13 | $0.18 | $0.29 | $0.29 | $0.06 |
| Avg Forecast | $0.03 | $0.04 | $0.01 | $-0.01 | $0.08 | $0.09 | $0.06 | $0.04 | $0.06 | $0.07 | $0.04 | $0.02 | $0.03 | $0.03 | $0.02 | $0.01 | $0.05 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 |
| High Forecast | $0.03 | $0.04 | $0.01 | $-0.01 | $0.08 | $0.09 | $0.06 | $0.04 | $0.07 | $0.08 | $0.04 | $0.02 | $0.03 | $0.03 | $0.02 | $0.01 | $0.05 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 |
| Low Forecast | $0.03 | $0.04 | $0.01 | $-0.01 | $0.08 | $0.08 | $0.06 | $0.04 | $0.05 | $0.07 | $0.04 | $0.02 | $0.03 | $0.02 | $0.01 | $0.01 | $0.05 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.78% | 0.76% | 26.00% | 13.27% | 23.20% | 16.57% | 9.00% |
According to 3 Wall Street analysts, Cellebrite DI's projected average Quarter EPS for Mar 23 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -80.20% decrease compared to CLBT previous annual EPS of $0.04 (Dec 22).